Deutsche Bank AG Purchases 17,763 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Deutsche Bank AG boosted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 14.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 137,932 shares of the company's stock after purchasing an additional 17,763 shares during the quarter. Deutsche Bank AG owned about 0.23% of Protagonist Therapeutics worth $5,324,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. BVF Inc. IL grew its holdings in Protagonist Therapeutics by 2.7% in the fourth quarter. BVF Inc. IL now owns 1,900,015 shares of the company's stock worth $73,341,000 after purchasing an additional 49,848 shares during the period. Pacer Advisors Inc. grew its holdings in Protagonist Therapeutics by 8.2% in the fourth quarter. Pacer Advisors Inc. now owns 1,876,466 shares of the company's stock worth $72,432,000 after purchasing an additional 142,376 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Protagonist Therapeutics by 6.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,392,652 shares of the company's stock worth $53,758,000 after purchasing an additional 83,185 shares during the period. Deep Track Capital LP purchased a new stake in Protagonist Therapeutics in the fourth quarter worth about $38,600,000. Finally, Wellington Management Group LLP grew its holdings in Protagonist Therapeutics by 3,025.4% in the fourth quarter. Wellington Management Group LLP now owns 940,077 shares of the company's stock worth $36,287,000 after purchasing an additional 909,998 shares during the period. Hedge funds and other institutional investors own 98.63% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. JMP Securities reiterated a "market outperform" rating and set a $58.00 price target on shares of Protagonist Therapeutics in a report on Friday, February 7th. BMO Capital Markets increased their price target on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. The Goldman Sachs Group cut their price target on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday, February 24th. HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Protagonist Therapeutics in a report on Monday. Finally, Truist Financial increased their price target on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a report on Tuesday, March 11th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $65.44.

Insiders Place Their Bets

In other Protagonist Therapeutics news, CFO Asif Ali sold 1,756 shares of the stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total value of $80,776.00. Following the transaction, the chief financial officer now directly owns 61,065 shares in the company, valued at approximately $2,808,990. This trade represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William D. Waddill sold 4,000 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the completion of the transaction, the director now owns 13,130 shares in the company, valued at $712,302.50. The trade was a 23.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,173 shares of company stock worth $3,461,180. Company insiders own 4.90% of the company's stock.

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock traded up $0.09 during midday trading on Thursday, reaching $45.91. 901,585 shares of the company traded hands, compared to its average volume of 879,124. The firm has a market capitalization of $2.85 billion, a price-to-earnings ratio of 17.26 and a beta of 2.65. The business has a 50 day moving average of $46.18 and a two-hundred day moving average of $42.61. Protagonist Therapeutics, Inc. has a 12 month low of $27.00 and a 12 month high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.31. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The business had revenue of $28.32 million for the quarter, compared to the consensus estimate of $30.44 million. As a group, equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.